Modality
mRNA
MOA
KRASG12Ci
Target
C5
Pathway
Autophagy
CF
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
~Jan 2021
→ ~Apr 2022
Phase 3
~Jul 2022
→ ~Oct 2023
NDA/BLA
~Jan 2024
→ ~Apr 2025
Approved
Jul 2025
→ Sep 2027
ApprovedCurrent
NCT04156517
1,206 pts·CF
2025-07→2027-09·Completed
1,206 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2027-09-031.4y awayPh3 Readout· CF
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3
Approved
Complet…
Catalysts
Ph3 Readout
2027-09-03 · 1.4y away
CF
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04156517 | Approved | CF | Completed | 1206 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| ALN-6288 | Alnylam | Approved | LAG-3 |